Results 121 to 130 of about 1,716,393 (201)

Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns. [PDF]

Clin Infect Dis
Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Weiner JA, Ackerman ME, Modlin JF, Sajjad OM, Arita M, Gast C, Mainou BA, Zaman K, Hoque M, Rana S, Bandyopadhyay AS, Wright PF.   +15 more
europepmc   +1 more source

Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey.

Lancet Glob Health, 2023
Kennedy SB, Macklin GR, Mason Ross G, Lopez Cavestany R, Moukom RA, Jones KAV, Mainou BA, Massaquoi MBF, Kieh MWS, Mach O.   +9 more
europepmc   +1 more source

Notes from the Field: Readiness for Use of Type 2 Novel Oral Poliovirus Vaccine in Response to a Type 2 Circulating Vaccine-Derived Poliovirus Outbreak - Tajikistan, 2020-2021. [PDF]

MMWR Morb Mortal Wkly Rep, 2022
O'Connor P, Huseynov S, Nielsen CF, Saidzoda F, Saxentoff E, Sadykova U, Kormoss P.   +6 more
europepmc   +1 more source

Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine. [PDF]

Vaccine X, 2021
Konz JO, Schofield T, Carlyle S, Wahid R, Ansari A, Strating JRPM, Yeh MT, Manukyan H, Smits SL, Tritama E, Rahmah L, Ugiyadi D, Andino R, Laassri M, Chumakov K, Macadam A.   +15 more
europepmc   +1 more source

Assessment of Oral Poliovirus Vaccine Viability and Titer at Delivery Points in Kinshasa, the Democratic Republic of the Congo: Implications for Cold Chain Management. [PDF]

Vaccines (Basel)
Kashitu-Mujinga G, Makaka-Mutondo A, Matondo-Kuamfumu M, Mambu-Mbika F, Bulabula-Penge J, Kabeya-Mampuela T, Nkawa F, Wanet-Tayele G, Nsunda-Makanzu B, Nsele-Muntatu P, Kabamba L, Nkuba-Ndaye A, Cikomola AMWB, Mukamba-Musenga E, Ahuka-Mundeke S.   +14 more
europepmc   +1 more source

Post-vaccination campaign evaluation of systemic and mucosal immunity of trivalent oral poliovirus vaccine in Karachi, Pakistan (2020-2021): a cross-sectional study. [PDF]

Lancet Reg Health Southeast Asia
Saleem AF, Jeyaseelan V, Kazi Z, Zehra M, Alam MM, Macklin G, Cavestany RL, Muhammad S, Rehman N, Mach O.   +9 more
europepmc   +1 more source

Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV). [PDF]

Pathogens
Badizadegan ND, Wassilak SGF, Estívariz CF, Wiesen E, Burns CC, Bolu O, Thompson KM.   +6 more
europepmc   +1 more source

Expected RATE of Vaccine-Associated Paralytic Poliomyelitis: A Simulation Analysis Regarding Transition from the Trivalent to Bivalent Oral Poliovirus Vaccine. [PDF]

Int J Prev Med, 2021
Yasri S, Wiwanitkit V.
europepmc   +1 more source

Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine. [PDF]

BMC Infect Dis
Xu J, Liu Y, Qiu W, Li W, Hu X, Li X, Fan Q, Tang W, Wang Y, Wang Q, Yao N.   +10 more
europepmc   +1 more source

Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV. [PDF]

Risk Anal, 2021
Kalkowska DA, Thompson KM.
europepmc   +1 more source